| Authors: |
Vrenken P; National and Kapodistrian University of Athens, Department of Pharmacy, Panepistimiopolis, Zografou, Greece; Bayer AG, Pharmacometrics/Modeling and Simulation, Model-Informed Drug Development, Leverkusen, Germany., Vertzoni M; National and Kapodistrian University of Athens, Department of Pharmacy, Panepistimiopolis, Zografou, Greece. Electronic address: vertzoni@pharm.uoa.gr., Frechen S; Bayer AG, Pharmacometrics/Modeling and Simulation, Model-Informed Drug Development, Leverkusen, Germany., Solodenko J; Bayer AG, Pharmacometrics/Modeling and Simulation, Model-Informed Drug Development, Leverkusen, Germany., Meyer M; Bayer AG, Pharmacometrics/Modeling and Simulation, Model-Informed Drug Development, Leverkusen, Germany., Muenster U; Bayer AG, Research and Development, Pharmaceutical Sciences, Advanced Drug Delivery, Wuppertal, Germany., Dallmann A; Bayer HealthCare SAS, Lille, France, on behalf of Bayer AG, Model-Informed Drug Development, Leverkusen, Germany. Electronic address: andre.dallmann@bayer.com. |
